PLASMA PROTEIN LEVEL RATIOS IDENTIFY NOVEL CIRCULATING TARGETS ASSOCIATED WITH STROKE RISK
Keywords:
Stroke, Mendelian randomization, Plasma proteins, Protein level ratiosAbstract
Previous studies have nominated individual plasma proteins as therapeutic targets for stroke. Whether ratios of protein levels, which can capture relative pathway activity, are causally related to stroke remains unknown. We evaluated the potential causal associations between plasma protein level ratios and stroke risk. We conducted bidirectional, two-sample Mendelian randomization (MR) to estimate the associations between circulating protein level ratios and overall stroke and stroke subtypes. Pathway enrichment and protein–protein interaction (PPI) analyses were used to explore potential mechanisms. Forward MR indicated that a higher TGFBR2/THBD ratio was associated with increased risk of any ischemic stroke (AIS) (OR = 1.15; 95% CI, 1.09–1.21; p = 4.07e-7). A higher GP1BA/SDC4 ratio was associated with increased risk of small-vessel stroke (SVS) (OR = 1.25; 95% CI, 1.14–1.37; p = 2.25e-6), whereas a higher SDC4/SEMA4D ratio was associated with lower SVS risk (OR = 0.82; 95% CI, 0.76–0.89; p = 1.18e-6). Reverse MR found no evidence that AIS or SVS causally influenced these ratios, supporting the inferred direction of effect. Sensitivity analyses supported the robustness of the estimates. Pathway enrichment and PPI analyses implicated TGF-β signaling and coagulation in AIS pathobiology, and platelet activation, extracellular matrix organization, and axon guidance in SVS. Plasma protein level ratios may help identify biologically relevant pathways and therapeutic targets for stroke prevention and treatment.References
[1] GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Neurology, 2021, 20(10): 795-820.
[2] NINDS Stroke Genetics Network (SiGN); International Stroke Genetics Consortium (ISGC). Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study. The Lancet Neurology, 2016, 15(2): 174-184.
[3] Bellenguez C, Bevan S, Gschwendtner A, et al. Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nature Genetics, 2012, 44(3): 328-333.
[4] Chauhan G, Arnold C, Chu A et al. Identification of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association studies. The Lancet Neurology, 2016, 15(7): 695-707.
[5] Kilarski L L, Achterberg S, Devan W J, et al. Meta-analysis in more than 17,900 cases of ischemic stroke reveals a novel association at 12q24.12. Neurology, 2014, 83(8): 678-685.
[6] Ferkingstad E, Sulem P, Atlason B A, et al. Large-scale integration of the plasma proteome with genetics and disease. Nature Genetics, 2021, 53(12): 1712-1721.
[7] Pietzner M, Wheeler E, Carrasco-Zanini J, et al. Mapping the proteo-genomic convergence of human diseases. Science, 2021, 374(6569): eabj1541.
[8] Gudjonsson A, Gudmundsdottir V, Axelsson G T, et al. A genome-wide association study of serum proteins reveals shared loci with common diseases. Nature Communications, 2022, 13(1): 480.
[9] Chen L, Peters J E, Prins B, et al. Systematic Mendelian randomization using the human plasma proteome to discover potential therapeutic targets for stroke. Nature Communications, 2022, 13(1): 6143.
[10] Zou X, Wang L, Wang S, et al. Promising therapeutic targets for ischemic stroke identified from plasma and cerebrospinal fluid proteomes: a multicenter Mendelian randomization study. International Journal of Surgery, 2024, 110(2): 766-776.
[11] Suhre K. Genetic associations with ratios between protein levels detect new pQTLs and reveal protein-protein interactions. Cell Genomics, 2024, 4(3): 100506.
[12] Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nature Genetics, 2018, 50(4): 524-537.
[13] Zhang Y Y, Chen B X, Yang Q, et al. The causal relationship between plasma protein-to-protein ratios and type 2 diabetes and its complications: proteomics Mendelian randomization study. Diabetes, Obesity and Metabolism, 2024, 26(10): 4410-4417.
[14] Burgess S, Davey Smith G, Davies N M, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Research, 2019, 4: 186.
[15] Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nature Communications, 2019, 10(1): 1523.
[16] Hollander M C, Latour L L, Yang D, et al. Attenuation of myeloid-specific TGFβ signaling induces inflammatory cerebrovascular disease and stroke. Circulation Research, 2017, 121(12): 1360-1369.
[17] Cole J W, Roberts S C, Gallagher M, et al. Thrombomodulin Ala455Val polymorphism and the risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women Study. BMC Neurology, 2004, 4(1): 21.
[18] Auro K, Komulainen K, Alanne M, et al. Thrombomodulin gene polymorphisms and haplotypes and the risk of cardiovascular events: a prospective follow-up study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26(4): 942-947.
[19] Olivot J M, Labreuche J, De Broucker T, et al. Thrombomodulin gene polymorphisms in brain infarction and mortality after stroke. Journal of Neurology, 2008, 255(4): 514-519.
[20] Poon E, Clermont F, Firpo M T, et al. TGFbeta inhibition of yolk-sac-like differentiation of human embryonic stem-cell-derived embryoid bodies illustrates differences between early mouse and human development. Journal of Cell Science, 2006, 119(Pt 4): 759-768.
[21] Mishra A, Malik R, Hachiya T, et al. Stroke genetics informs drug discovery and risk prediction across ancestries. Nature, 2022, 611(7934): 115-123.
[22] Hazelwood H S, Frank J A, Maglinger B, et al. Plasma protein alterations during human large vessel stroke: a controlled comparison study. Neurochemistry International, 2022, 160: 105421.
[23] Solbu M D, Kolset S O, Jenssen T G, et al. Gender differences in the association of syndecan-4 with myocardial infarction: the population-based Tromsø Study. Atherosclerosis, 2018, 278: 166-173.
[24] Strand M E, Aronsen J M, Braathen B, et al. Shedding of syndecan-4 promotes immune cell recruitment and mitigates cardiac dysfunction after lipopolysaccharide challenge in mice. Journal of Molecular and Cellular Cardiology, 2015, 88: 133-144.
[25] Janssen B J, Robinson R A, Pérez-Brangulí F, et al. Structural basis of semaphorin-plexin signalling. Nature, 2010, 467(7319): 1118-1122.
[26] Kumanogoh A, Kikutani H. Biological functions and signaling of a transmembrane semaphorin, CD100/Sema4D. Cellular and Molecular Life Sciences, 2004, 61(3): 292-300.
[27] Zhou Y F, Li Y N, Jin H J, et al. Sema4D/PlexinB1 inhibition ameliorates blood-brain barrier damage and improves outcome after stroke in rats. The FASEB Journal, 2018, 32(4): 2181-2196.
[28] Wada T, Sawano T, Tanaka T, et al. Absence of Sema4D improves oligodendrocyte recovery after cerebral ischemia/reperfusion injury in mice. Neuroscience Research, 2016, 108: 6-11.